Cefotaxime Sodium Ameliorates Infection Control and Inflammatory Response in Patients With Nosocomial Infection During Decompensated Cirrhosis.

It was to evaluate the efficacy and safety of cefotaxime sodium in the treatment of patients with decompensated cirrhosis complicated by nosocomial infections. A retrospective analysis was conducted on 112 patients with decompensated cirrhosis, who were categorized into two groups based on treatment regimen: the antibiotic group (AG) and the conventional group (CG). Differences between the two groups were compared in terms of clinical infections, serum inflammatory markers, microbial clearance rates, therapeutic efficacy, and adverse reactions. After treatment, the AG exhibited significantly lower white blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP), and interleukin-1β (IL-1β) compared with the CG, indicating the advantage of cefotaxime sodium in alleviating inflammation. The incidence of nosocomial infections was lower in the AG, and the microbial clearance rate (93.85%) was significantly higher than that of the CG (82.98%). Clinical efficacy, as evaluated by the patient-generated subjective global assessment (PG-SGA) score, was significantly superior in the AG, with a lower incidence of adverse reactions. The overall effective rate in the AG was 96.92%, significantly higher than the 87.23% in the CG (p < 0.05). Cefotaxime sodium demonstrated outstanding performance in controlling infections, reducing inflammatory responses, and improving nutritional status in patients with decompensated cirrhosis complicated by nosocomial infections. It is an effective and safe treatment option for such patients.